Irinotecan- vs oxaliplatin-based regimens for neoadjuvant chemotherapy in colorectal liver metastasis patients: A retrospective study

Table 3 Univariable and multivariable analyses of factors associated with progression-free survival

Variable	Univariable analysis			Multivariable analysis
	HR	95%CI	P value	HR	95%CI	P value
Age, yr
> 60	Ref
≤ 60	0.878	0.682-1.131	0.314
Gender
Male	Ref
Female	0.949	0.733-1.230	0.694
Primary T stage
1-2	Ref
3-4	1.183	0.820-1.706	0.369
Primary N stage
N0	Ref
N1-2	1.090	0.952-1.248	0.212
Location tumor
Colon	Ref
Rectum	0.869	0.676-1.116	0.270
Primary tumor location
Left	Ref			Ref
Right	1.508	1.072-2.121	0.018	1.413	0.991-2.015	0.056
Disease-free interval
> 12 mo	Ref			Ref
≤ 12 mo	1.487	1.068-2.071	0.019	1.156	0.788-1.696	0.459
CEA
≤ 200	Ref
> 200	1.340	0.689-2.607	0.388
CA 19-9
≤ 100	Ref			Ref
> 100	1.528	1.077-2.167	0.017	1.521	1.032-2.241	0.034
Tumor size
≤ 5 cm	Ref			Ref
> 5 cm	1.149	1.019-1.554	0.028	1.479	1.062-2.060	0.021
Tumor no.
≤ 1	Ref			Ref
> 1	1.702	1.284-2.255	0.000	1.446	1.077-2.146	0.014
CRS
0-2	Ref			Ref
3-5	1.665	1.298-2.135	0.000	1.256	0.894-1.765	0.189
RAS status
Wild	Ref			Ref
Mutation	1.641	1.276-2.110	0.000	1.468	1.127-1.913	0.004
Extrahepatic metastases
No	Ref
Yes	1.081	0.781-1.496	0.638
Biological agent
Cetuximab
Bevacizumab	Ref
No	1.057	0.910-1.228	0.469
Response
Complete response
Partial response
Stable disease	Ref			Ref
Progressive disease	1.564	1.067-2.292	0.022	1.830	1.211-2.764	0.004
Hepatic resection
Minor	Ref
Major	0.997	0.753-1.320	0.984
Concomitant ablation
No	Ref			Ref
Yes	1.634	1.195-2.236	0.002	1.002	0.641-1.568	0.992
Stage resection
No	Ref
Yes	0.839	0.682-1.033	0.098
Margin status
R0	Ref
R1	0.878	0.581-1.327	0.537
Distribution
Unilobar	Ref			Ref
Bilobar	1.277	1.067-1.528	0.008	1.112	0.875-1.413	0.385
Extrahepatic metastases
Yes	Ref
No	1.081	0.781-1.496	0.638
Adjuvant chemotherapy
No	Ref
Yes	0.885	0.654-1.198	0.430
Clavien-Dino classification
I-II	Ref
III-V	1.018	0.833-1.244	0.859
RBC transfusion
Yes	Ref
No	0.857	0.456-1.614	0.634

PFS: Progression-free survival; HR: Hazard ratio; CEA: Carcinoembryonic antigen; CA 19-9: Carbohydrate antigen 19-9; RBC: Red blood cell; CI: Confidence interval; CRS: Clinical risk score.